Thursday, November 12, 2009

Amgen to Present at 18th Annual Credit Suisse Healthcare Conference

THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Thursday, November 05, 2009

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.  Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.

Read the rest of this entry

Posted in Press Releases

Wednesday, November 04, 2009

Call for Applications: The Amgen Award for Science Teaching Excellence

THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE).  This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates.

Read the rest of this entry

Posted in Press Releases

Friday, October 30, 2009

Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints

THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovascular morbidity, including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia, or end-stage renal disease (ESRD).

Read the rest of this entry

Posted in Press Releases

Wednesday, October 21, 2009

Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49

THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008.

Read the rest of this entry

Posted in Press Releases